HRT for Perimenopause: What the Evidence Shows

For years, Hormone Replacement Therapy (HRT) came with a long list of warnings that made many women understandably hesitant to consider it. But the evidence around HRT has evolved, especially for women going through perimenopause. What we know now is more layered than simply labeling hormone therapy “safe” or “risky.” Your age, health history, the type of HRT you use, and when you start can all change the picture. So, what does the research actually show about HRT during perimenopause? Let’s break down what has changed, what we know today, and what’s still worth discussing with your clinician.

Key takeaways:

• Hormone fluctuations during perimenopause can trigger hot flashes, brain fog, sleep changes, and other symptoms
• HRT can help manage perimenopause symptoms, but benefits and risks depend on your age, health history, timing, and formulation
• Research suggests HRT has a more favorable risk profile when started during or closer to the menopause transition
• Transdermal estrogen bypasses the liver and may be preferred for women with certain cardiovascular or clotting risk factors
• HRT isn’t right for everyone, so treatment should be personalized with a clinician

What Happens to Your Hormones During Perimenopause?

During perimenopause, estrogen and progesterone begin to fluctuate as the ovaries transition toward menopause. This phase typically begins in your 40s and can last several years, but hormone levels rarely follow a smooth, predictable decline.

Estrogen, for example, can rise and fall by a wide margin, sometimes within the same cycle. The brain senses these changes and releases more follicle-stimulating hormone (FSH) in an effort to encourage the ovaries to produce estrogen. The result can feel a little like a hormonal roller coaster instead of a steady downhill slope.

Progesterone changes, too. Because progesterone production depends on ovulation, levels can become more unpredictable as ovulation becomes less regular. Together, these shifting hormones can affect sleep, mood, body temperature, and concentration. That’s why symptoms like hot flashes, night sweats, and brain fog can show up during perimenopause even when estrogen isn’t consistently “low.” Research into delaying menopause is also looking into how this transition window could be slowed through maintaining ovarian healthspan.

What Is HRT?

Hormone Replacement Therapy (HRT) works by replacing hormones the ovaries are no longer producing as consistently during perimenopause, primarily estrogen and, in most cases, a progestogen. For women who still have their uterus, which is the common scenario, estrogen is combined with a progestogen (either bioidentical progesterone or a synthetic form) to protect the uterine lining. For women who have had a hysterectomy, estrogen alone is typically appropriate.

Estrogen-Only HRT

Estrogen-only HRT is typically prescribed to women who have had a hysterectomy. If you still have a uterus, estrogen is generally combined with a progestogen. This is because estrogen can stimulate the uterine lining, while progestogen helps protect against the increased risk of endometrial cancer.

HRT vs. Hormonal Birth Control

HRT is different from hormonal birth control, even though both can contain estrogen and progestogen. Birth control is designed to prevent pregnancy, often by suppressing ovulation. HRT uses hormones differently, with the goal of helping manage symptoms related to the hormonal changes of perimenopause and menopause.

Types of HRT Available During Perimenopause

HRT during perimenopause can be systemic or local, depending on which symptoms you’re trying to ease. Systemic HRT delivers estrogen throughout the body and can help with symptoms like hot flashes, sleep changes, and mood swings. Local estrogen acts primarily in vaginal tissue and is used for symptoms like vaginal dryness and discomfort.

How HRT is delivered matters, too. Each format works a little differently and can have different risk profiles. The chart below breaks down the key differences.

Delivery Format	How It Works	Key Consideration
Oral tablets	Swallowed; estrogen passes through the liver before entering the bloodstream	First-pass liver metabolism may raise clotting proteins; not preferred for women with clotting risk factors
Transdermal patches, gels, sprays	Estradiol absorbed through the skin directly into the bloodstream	Bypasses liver metabolism; often preferred for women with cardiovascular or clotting risk factors
Vaginal rings (systemic dose)	Higher-dose ring releases estrogen absorbed into the bloodstream	Delivers systemic estrogen; suited for women who prefer a low-maintenance format
Local vaginal creams, suppositories, low-dose rings	Act only in vaginal tissue; minimal systemic absorption	Treats genitourinary symptoms (dryness, discomfort) only; does not relieve hot flashes, sleep issues, or mood changes
Oral micronized progesterone	Bioidentical progesterone taken by mouth; protects the uterine lining	More favorable profile than synthetic progestogens based on current observational data
Levonorgestrel IUS	Progestogen delivered locally to the uterus via an intrauterine system	Provides uterine protection without systemic progestogen exposure

Choosing among these options depends on your symptom picture, personal health history, and how you prefer to use the treatment. Your clinician will factor all of that in when designing a women’s hormone care plan.

What Does the Research Show About HRT for Perimenopause?

Much of the debate around HRT today can be traced back to the Women’s Health Initiative and how our understanding of its findings has changed over time.

In 2002, the Women’s Health Initiative (WHI) reported findings linking certain forms of HRT to increased risks of breast cancer and cardiovascular events. The results changed prescribing almost overnight. But the women in the study were 50 to 79 years old, with an average age of about 63. Many were well beyond perimenopause when they started treatment, raising questions about how directly those findings applied to women beginning HRT earlier in the menopause transition.

Longer-term WHI research added important context. Over 18 years of follow-up, HRT was not associated with a meaningful increase or decrease in overall all-cause, cardiovascular, or cancer mortality across the full study population. Outcomes also varied by age and the type of hormone therapy used, showing why the potential benefits and risks of HRT can differ from one person to another.

As the evidence has evolved, so has the regulatory guidance. In November 2025, the FDA began removing broad boxed-warning language about cardiovascular disease, breast cancer, and probable dementia from menopausal HRT labeling after reviewing the scientific literature. In February 2026, the FDA approved updated labeling for the first six menopausal hormone therapy products.

Rather than asking whether HRT is simply “safe” or “unsafe,” current research points to more specific questions: How old are you? What is your health history? Which hormones are being used? And when did treatment begin?

That last question has become especially important in HRT research.

Why Does the Timing of HRT in Perimenopause Matter?

When you start HRT may matter almost as much as whether you start it at all. Research increasingly suggests that beginning Hormone Replacement Therapy during or closer to the menopause transition may carry a different benefit and risk profile than starting years later.

This idea is known as the “timing hypothesis.” A large-scale 2025 analysis presented at The Menopause Society’s Annual Meeting found that women who began estrogen during perimenopause and used it for at least 10 years before menopause did not have meaningfully higher associated rates of breast cancer, heart attack, or stroke compared with non-users. The finding is encouraging, but it comes from observational research, so it cannot prove that starting earlier directly caused those outcomes.

Why might timing make a difference? One theory is that tissues that have been exposed to estrogen for decades may respond differently to Hormone Therapy than tissues that have gone years with much lower estrogen levels. In other words, starting HRT earlier in the transition may not be biologically equivalent to starting it much later.

For women already experiencing perimenopause symptoms, this is one reason the decision about HRT does not necessarily have to wait until periods stop completely. Timing is only one part of the picture, though. Your symptoms, health history, and individual risk factors still determine whether starting HRT makes sense for you.

Who Is a Good Candidate for HRT?

Good candidates for HRT during perimenopause are generally women who are still within the menopause transition, meaning they are still having periods, even if irregular, and who are experiencing moderate to severe symptoms that affect their quality of life. Age alone is not the defining criterion; the clinical picture depends far more on where someone is in the transition and what their symptom burden actually looks like. Once a person’s last menstrual period has passed, they are by definition postmenopausal, and HRT candidacy at that stage is a distinct clinical conversation shaped by how much time has elapsed since menopause, overall cardiovascular health, and individual risk factors.

HRT may be especially important for women with premature ovarian insufficiency or early menopause before age 45. Longer estrogen deficiency at a younger age may be associated with concerns like accelerated bone loss and increased cardiovascular risk. For this group, HRT is often recommended at least until the average age of natural menopause.

When HRT Requires a Closer Look

Some health factors call for a more careful conversation instead of an automatic yes or no:

• A personal history of hormone-sensitive cancers, such as estrogen-receptor-positive breast cancer
• Active cardiovascular disease, a history of venous thromboembolism, or untreated high blood pressure
• Unexplained uterine bleeding that has not yet been checked by a clinician

Ultimately, HRT candidacy is personal. A US-licensed clinician can look at your symptoms alongside your personal and family health history, risk factors, and goals to determine whether HRT is appropriate for you. No symptom quiz or checklist can replace that full clinical picture.

HRT Risks and Side Effects

HRT comes with potential risks and side effects during perimenopause, but there’s no single risk profile that applies to every woman. Your age, health history, when you start, how long you use HRT, and even how you take it can all change the picture. Instead of treating HRT as simply “safe” or “risky,” it’s more useful to look at what the evidence actually says about the concerns women hear most often. The table below breaks down four of the big ones.

Concern	What the Evidence Shows	Key Nuance
Breast cancer	Estrogen-only HRT appears to carry little to no increase in breast cancer risk based on current evidence. Combined estrogen and synthetic progesterone therapy is associated with a small increase in risk with longer use.	Current observational data suggest oral micronized progesterone may have a more favorable risk profile than synthetic progestogens.
Cardiovascular risk	Transdermal estrogen is generally preferred for women with cardiovascular or clotting risk factors because it bypasses the liver and is thought to have less effect on clotting proteins than oral estrogen.	For women who start HRT earlier without pre-existing cardiovascular disease, current evidence does not suggest the same level of risk seen in older women who started therapy later.
Weight gain	Available clinical trial data have not shown meaningful weight gain as a direct effect of Hormone Therapy.	Weight changes during perimenopause reflect many factors: shifting hormones, metabolism, sleep, and body composition. See our guide to biology and weight for more.
Dementia	Dementia concerns largely trace back to the original WHI findings in older women who began HRT later in life.	Some subsequent analyses have not shown the same pattern among women who begin therapy closer to the menopause transition.

HRT is the most studied option for perimenopausal symptoms, but several evidence-supported non-hormonal approaches exist, from FDA-approved medications to lifestyle interventions with varying levels of trial data.

What Are the Non-Hormonal Alternatives to HRT?

HRT isn’t the right choice for everyone, and some women simply prefer a non-hormonal approach. Several options can help manage perimenopause symptoms, although their effectiveness varies depending on the symptom and individual.

Prescription medications: FDA-approved non-hormonal options include fezolinetant and elinzanetant, which target brain pathways involved in controlling body temperature and may help reduce hot flashes. Low-dose paroxetine is also FDA-approved for vasomotor symptoms, while other SSRIs and SNRIs, including venlafaxine and escitalopram, may be used off-label.

Lifestyle and behavioral approaches: Cognitive behavioral therapy may help make hot flashes feel less disruptive, while practical changes like maintaining a healthy weight and limiting alcohol may also help. Other longevity tools can support women’s health more broadly during this transition.

Herbal remedies and phytoestrogens are also commonly marketed for menopause symptoms, but the evidence is less consistent. “Natural” doesn’t automatically mean effective or risk-free, so these are still worth discussing with a clinician.

Women’s Hormone Care at AgelessRx

For decades, much of medical research has centered on men, leaving important gaps in how we understand women’s health, especially through perimenopause, menopause, and beyond. At AgelessRx, we believe women deserve the same depth of attention to the science of living longer and feeling better while doing it.

That’s a big part of why we built Women’s Hormone Care. Our approach looks beyond a single hormone level or symptom to consider what’s changing across this stage of life and which options may make the most sense. Every treatment we offer is reviewed by our Scientific Advisory Board and in-house Research Team, with factors like formulation, timing, symptoms, and health history helping guide care.

If you’re working through perimenopause and wondering what your options are, our US-licensed clinicians can review your symptoms, health history, and individual risk factors and help you build a plan grounded in the latest evidence.

Note: The above statements have not been reviewed by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.